NCT06017271|Withdrawn
Study Stopped
The number of patients is not sufficient to support the project.
Loading search results
Sponsor study identifier
observational
0
1 country
1
Study Start
May 1, 2024
Actual (reported)Primary Completion
July 15, 2024
Actual (reported)Study Completion
July 19, 2024
Actual (reported)The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 19, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 24, 2023
Actual (reported)August 30, 2023
Actual (reported)May 1, 2024
Actual (reported)July 15, 2024
Actual (reported)July 19, 2024
Actual (reported)EAT volume
volume of epicardial adipose tissue (EAT), Cm3
May, 20, 2023
EAT density
density of epicardial adipose tissue (EAT) , Hounsfield Units (HU)
May, 20, 2023
The CTPA diagnosis suggest pulmonary embolism
The CTPA diagnosis did not suggest pulmonary embolism
The CTPA diagnosis suggest or did not suggest pulmonary embolism.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
This study was conducted on patients with a confirmed diagnosis of Lung Cancer who were admitted to the First Affiliated Hospital of Xi'an Jiaotong University from 1 January 2012 to 31 December 2021. Patients who did not meet any of the inclusion criteria or met any of the exclusion criteria were excluded. The subjects were divided into PE group and control group according to the results of CTPA examination, and the patients in the two groups were matched by gender and age 1:1 tendency score.
First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, 710061, China
Yang Yan
First Affiliated Hospital Xi'an Jiaotong University
Haichen Wang
First Affiliated Hospital Xi'an Jiaotong University
0 participants (actual enrollment reported by the registry).
First Submitted
August 24, 2023
First Posted
August 30, 2023
Study Start
May 1, 2024
Actual (reported)Observation on the Frailty Status of Lung Cancer Patients
Contact the study team to confirm eligibility.
Primary Completion
July 15, 2024
Actual (reported)Study Completion
July 19, 2024
Actual (reported)Last Updated
July 22, 2024
Record last verified: 2024-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: